Media ReleasesNyrada

View All Nyrada News


Nyrada - Improved Drug Candidate Selected for WRAIR Studies


Nyrada Inc (ASX: NYR), a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announces the selection of a new version of its brain injury candidate (NYR-BI01) to be taken forward into its collaboration studies with WRAIR. NYR-BI01 is a more potent and druglike version of its predecessor, NYX-1010.

NYR-BI01 showed high potency in a biological assay and impressive drug-like characteristics in a pharamacokinetic (PK) study (see results below in Figure 1), intended to determine the level at which it penetrates the brain.

For more information, download the attached PDF.


Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.